Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Encorafenib Plus Binimetinib in Patients With Locally Advanced, Unresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, Multinational, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland - BERING MELANOMA

NCT04045691 is registered in ClinicalTrials.gov with Pierre Fabre Pharma GmbH as lead sponsor.

NCT NCT04045691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04045691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Encorafenib Plus Binimetinib in Patients With Locally Advanced, Unresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, Multinational, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland - BERING MELANOMA
Lead sponsor
Pierre Fabre Pharma GmbH
Phase
Observational
Overall status
Recruiting
Start date
October 17, 2019
Completion date
September 30, 2027
Enrollment
750 (estimated)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii, melanoma stage iv